Alnylam expands AI partnership with Komodo Health

Alnylam Pharmaceuticals (ALNY) has expanded its collaboration with Komodo Health, extending use of Komodo’s Marmot analytics AI platform from commercial operations to broader enterprise functions across the company’s customer-facing organization.

Alnylam Pharmaceuticals’ share price has been under pressure, with the stock down 27.19% on a year to date basis and 11.94% over 90 days, while the 5 year total shareholder return of 69.96% points to stronger longer term momentum.

If this use of AI in healthcare is on your radar, it could be a good moment to widen your watchlist with 40 healthcare AI stocks

With Alnylam Pharmaceuticals’ share price under pressure despite analyst targets and intrinsic estimates that sit well above the last close, the key question for investors is whether the stock is still undervalued or if the market is already pricing in future growth.

Most Popular Narrative: 47% Undervalued

Compared with Alnylam Pharmaceuticals’ last close at $291.37, the most widely followed narrative points to a fair value of $550, implying a sizable gap in expectations.

The bullish analysts expect earnings to reach $3.6 billion (and earnings per share of $22.69) by about June 2029, up from $538.0 million today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $1.3 billion.

Curious what kind of revenue climb and margin profile would need to sit behind that earnings leap, and what sort of valuation multiple those assumptions lean on? The full narrative lays out a detailed set of growth, profitability, and discount rate inputs that join together to reach the $550 figure, along with how those views compare with the rest of the analyst community.

Result: Fair Value of $550 (UNDERVALUED)

However, the bullish Alnylam Pharmaceuticals narrative could be knocked off course if AMVUTTRA underperforms expectations or if pricing and rebate pressures squeeze margins harder than assumed.

Another View: What Multiples Say About Alnylam Pharmaceuticals

While the Alnylam Pharmaceuticals narrative leans on discounted cash flows and long term earnings power, the current P/E of 72.3x tells a tougher story. It sits well above the US Biotechs industry at 17.2x, the peer average at 29.4x, and even the 32x fair ratio that the market could move toward.

This kind of gap can mean investors are paying up heavily for future growth, so the key question is whether the earnings path here truly justifies such a premium.

Next Steps

If this mix of optimism and skepticism around Alnylam Pharmaceuticals has you thinking, take a moment to review the figures yourself and decide quickly what they really imply about the company’s potential, starting with its 4 key rewards

Looking for more investment ideas beyond Alnylam Pharmaceuticals?

If Alnylam Pharmaceuticals has sharpened your focus on quality and valuation, do not stop here. Broaden your opportunity set with a few targeted stock ideas.

• Target potential mispricings by scanning companies that combine quality metrics with attractive valuations through the 44 high quality undervalued stocks.
• Strengthen your focus on resilience by reviewing companies highlighted in the 69 resilient stocks with low risk scores that score well on business and balance sheet risk factors.
• Spot potential up and comers early by checking the screener containing 19 high quality undiscovered gems that pair solid fundamentals with lower market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.